TABLE 2.
MICs of various β-lactam/β-lactamase inhibitor combinations against 8 clinical SME-producing S. marcescens isolates
| Isolate | MIC (mg/liter) ofa: |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAZ | CAZ-AVI | CAZ-REL | CAZ-VAB | IMI | IMI-AVI | IMI-REL | IMI-VAB | MER | MER-AVI | MER-REL | MER-VAB | |
| SM-1 | 1 | 0.25 | 0.25 | 0.25 | ≥256 | 8 | 128 | 2 | 128 | 2 | 8 | 0.125 |
| SM-2 | 0.5 | 0.125 | 0.25 | 0.25 | ≥256 | 8 | ≥256 | 4 | 128 | 1 | 64 | ≤0.03 |
| SM-3 | 0.125 | 0.125 | 0.25 | 0.125 | ≥256 | 8 | 64 | 2 | 128 | 2 | 64 | ≤0.03 |
| SM-4 | 1 | 0.25 | 0.25 | 0.125 | ≥256 | 8 | 128 | 2 | 128 | 2 | 16 | 0.125 |
| SM-5 | 0.5 | 0.125 | 0.5 | 0.5 | ≥256 | 8 | ≥256 | 2 | 128 | 1 | 16 | ≤0.03 |
| SM-6 | 1 | 0.125 | 0.25 | 0.25 | ≥256 | 8 | ≥256 | 2 | 128 | 16 | 32 | ≤0.03 |
| SM-7 | 0.5 | 0.125 | 0.25 | 0.25 | ≥256 | 16 | 64 | 2 | 128 | 0.25 | 1 | ≤0.03 |
| SM-8 | 0.25 | 0.06 | 0.25 | 0.25 | ≥256 | 8 | ≥256 | 2 | ≥256 | 16 | 32 | ≤0.03 |
a
Avibactam and relebactam were tested at a fixed concentration of 4 mg/liter; vaborbactam was tested at a fixed concentration of 8 mg/liter. CAZ, ceftazidime; AVI, avibactam; REL, relebactam; VAB, vaborbactam; IMI, imipenem; MER, meropenem.